» Articles » PMID: 8647216

Affinity Maturation and Hypermutation in a Simulation of the Humoral Immune Response

Overview
Journal Eur J Immunol
Date 1996 Jun 1
PMID 8647216
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

By experimenting with a cellular automaton model of the immune system, we have reproduced affinity maturation of the antibody response, a somatic adaptation to a changing environment. The simulation allowed the isolation of a number of variables, e.g. the fraction of repertoire available, the magnitude of the change in affinity with mutation, the mutation frequency and its focus on the complementarity-determining regions (CDR) of the antibody. Multiple series of immunizations were run in machina where the contribution of each variable was evaluated against the maturation observed. We found that hypermutation is not necessary for affinity maturation if the repertoire of B cell specificities is sufficiently complete, but is essential when the B cell diversity is limited (which happens to be the case in vivo), as it fills the holes in the repertoire and allows selection by antigen. Maturation also depends on the magnitude of the change in affinity with mutation, and we supply some necessary limits on this parameter. For mutations confined to the CDR, the most efficient maturation occurs at mutation rates of 0.2 per paratope and per cell division. When mutations also affect the framework regions, the peak of the most effective CDR mutation rate moves progressively to lower values. A most sensitive parameter is the speed of maturation, which reflects the rate of expansion of mutated clones. Comparing it with biological observations can help to discriminate between alternative hypotheses on the phenomena of hypermutation and affinity.

Citing Articles

Design of immunogens for eliciting antibody responses that may protect against SARS-CoV-2 variants.

Wang E, Chakraborty A PLoS Comput Biol. 2022; 18(9):e1010563.

PMID: 36156540 PMC: 9536555. DOI: 10.1371/journal.pcbi.1010563.


Targeting the SARS-CoV2 nucleocapsid protein for potential therapeutics using immuno-informatics and structure-based drug discovery techniques.

Kwarteng A, Asiedu E, Sakyi S, Opoku Asiedu S Biomed Pharmacother. 2020; 132:110914.

PMID: 33254432 PMC: 7574726. DOI: 10.1016/j.biopha.2020.110914.


Computer Modeling of Clonal Dominance: Memory-Anti-Naïve and Its Curbing by Attrition.

Castiglione F, Ghersi D, Celada F Front Immunol. 2019; 10:1513.

PMID: 31338096 PMC: 6626922. DOI: 10.3389/fimmu.2019.01513.


MiStImm: an agent-based simulation tool to study the self-nonself discrimination of the adaptive immune response.

Kerepesi C, Bakacs T, Szabados T Theor Biol Med Model. 2019; 16(1):9.

PMID: 31046789 PMC: 6498635. DOI: 10.1186/s12976-019-0105-5.


Current Strategies and Applications for Precision Drug Design.

Wang C, Xu P, Zhang L, Huang J, Zhu K, Luo C Front Pharmacol. 2018; 9:787.

PMID: 30072901 PMC: 6060444. DOI: 10.3389/fphar.2018.00787.